{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:53:16Z","timestamp":1790182396959,"version":"4.1.0"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013733","name":"Ipsen Biopharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013733","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Progressive Familial intrahepatic cholestasis (PFIC) are rare disorders of bile acid (BAs) secretion and transport with a genetic background. PFIC are paediatric manifestations, but the same variants causing PFIC can also cause cholestasis with a later paediatric onset or adult-onset cholestatic disease (AOCD). Pruritus is a symptom of cholestasis that can be so devastating that it requires a liver transplant (LT) in children; some PFIC types have been described as at risk of liver cancer development. Commonly prescribed medications for PFIC symptoms can partially relieve pruritus without changing the natural history of the disease. Recently, a therapy reducing the intestinal resorption of BAs has been approved; it is effective on both pruritus and cholestasis in PFIC, potentially being a disease-modifying intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Areas covered<\/jats:title>\n                    <jats:p>The clinical and genetic characteristics of different PFIC and AOCD are summarized to provide a common background for geneticists and paediatric and adult hepatologists in diagnosis and management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Expert opinion<\/jats:title>\n                    <jats:p>Collaboration between paediatric and adult hepatologists and geneticists will become crucial for cholestatic disease research and patient treatment. Therefore, adult hepatologists will need to learn more about FIC. This might enable the implementation of individualized surveillance in FIC patients and the evaluation of patient family histories.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-03599-2","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:56:48Z","timestamp":1740131808000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Genotypes and different clinical variants between children and adults in progressive familial intrahepatic cholestasis: a state-of-the-art review"],"prefix":"10.1186","volume":"20","author":[{"given":"Giovanni","family":"Vitale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Sciveres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Mandato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9367-4909","authenticated-orcid":false,"given":"Adamo Pio","family":"d\u2019Adamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Di Giorgio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"key":"3599_CR1","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/J.DLD.2019.04.013\/ASSET\/D0C16C98-9DA9-4CA4-843A-DDCB5D5F52D4\/MAIN.ASSETS\/GR2.SML","volume":"51","author":"G Vitale","year":"2019","unstructured":"Vitale G, Gitto S, Vukotic R, Raimondi F, Andreone P. Familial intrahepatic cholestasis: new and wide perspectives. Dig Liver Dis. 2019;51:922\u201333. https:\/\/doi.org\/10.1016\/J.DLD.2019.04.013\/ASSET\/D0C16C98-9DA9-4CA4-843A-DDCB5D5F52D4\/MAIN.ASSETS\/GR2.SML.","journal-title":"Dig Liver Dis"},{"key":"3599_CR2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/J.CLINRE.2018.07.010","volume":"43","author":"A Baker","year":"2019","unstructured":"Baker A, Kerkar N, Todorova L, Kamath BM, Houwen RHJ. Systematic review of progressive familial intrahepatic cholestasis. Clin Res Hepatol Gastroenterol. 2019;43:20\u201336. https:\/\/doi.org\/10.1016\/J.CLINRE.2018.07.010.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"3599_CR3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1080\/14737167.2021.1859371\/SUPPL_FILE\/IERP_A_1859371_SM4029.DOCX","volume":"21","author":"L Ruiz-Casas","year":"2021","unstructured":"Ruiz-Casas L, O\u2019Hara S, Mighiu C, Finnegan A, Taylor A, Ventura E, Dhawan A, Murray KF, Schattenberg J, Willemse J, et al. Burden of illness of progressive familial intrahepatic cholestasis in the US, UK, France, and Germany: study rationale and protocol of the PICTURE Study. Expert Rev Pharmacoecon Outcomes Res. 2021;21:247\u201353. https:\/\/doi.org\/10.1080\/14737167.2021.1859371\/SUPPL_FILE\/IERP_A_1859371_SM4029.DOCX.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"3599_CR4","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/J.CLD.2018.06.003","volume":"22","author":"LN Bull","year":"2018","unstructured":"Bull LN, Thompson RJ. progressive familial intrahepatic cholestasis. Clin Liver Dis. 2018;22:657\u201369. https:\/\/doi.org\/10.1016\/J.CLD.2018.06.003.","journal-title":"Clin Liver Dis"},{"key":"3599_CR5","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1002\/HEP.31087","volume":"71","author":"E Gao","year":"2020","unstructured":"Gao E, Cheema H, Waheed N, Mushtaq I, Erden N, Nelson-Williams C, Jain D, Soroka CJ, Boyer JL, Khalil Y, et al. organic solute transporter alpha deficiency: a disorder with cholestasis, liver fibrosis, and congenital diarrhea. Hepatology. 2020;71:1879\u201382. https:\/\/doi.org\/10.1002\/HEP.31087.","journal-title":"Hepatology"},{"key":"3599_CR6","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1002\/HEP.29516","volume":"68","author":"M Sultan","year":"2018","unstructured":"Sultan M, Rao A, Elpeleg O, Vaz FM, Abu-Libdeh B, Karpen SJ, Dawson PA. Organic solute transporter-beta (SLC51B) deficiency in two brothers with congenital diarrhea and features of cholestasis. Hepatology. 2018;68:590. https:\/\/doi.org\/10.1002\/HEP.29516.","journal-title":"Hepatology"},{"key":"3599_CR7","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.jpeds.2021.09.019","volume":"240","author":"A Stalke","year":"2022","unstructured":"Stalke A, Sgodda M, Cantz T, Skawran B, Lainka E, Hartleben B, Baumann U, Pfister ED. KIF12 variants and disturbed hepatocyte polarity in children with a phenotypic spectrum of cholestatic liver disease. J Pediatr. 2022;240:284-291.e9. https:\/\/doi.org\/10.1016\/j.jpeds.2021.09.019.","journal-title":"J Pediatr"},{"key":"3599_CR8","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1136\/JMEDGENET-2019-106706","volume":"58","author":"W Luan","year":"2021","unstructured":"Luan W, Hao CZ, Li JQ, Wei Q, Gong JY, Qiu YL, Lu Y, Shen CH, Xia Q, Xie XB, et al. Biallelic loss-of-function ZFYVE19 mutations are associated with congenital hepatic fibrosis, sclerosing cholangiopathy and high-GGT cholestasis. J Med Genet. 2021;58:514\u201325. https:\/\/doi.org\/10.1136\/JMEDGENET-2019-106706.","journal-title":"J Med Genet"},{"key":"3599_CR9","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.3390\/CANCERS14143421","volume":"14","author":"G Vitale","year":"2022","unstructured":"Vitale G, Mattiaccio A, Conti A, Turco L, Seri M, Piscaglia F, Morelli MC. Genetics in familial intrahepatic cholestasis: clinical patterns and development of liver and biliary cancers: a review of the literature. Cancers. 2022;14:3421. https:\/\/doi.org\/10.3390\/CANCERS14143421.","journal-title":"Cancers"},{"key":"3599_CR10","doi-asserted-by":"publisher","first-page":"5105","DOI":"10.1007\/S12325-022-02262-7","volume":"39","author":"C Gwaltney","year":"2022","unstructured":"Gwaltney C, Ivanescu C, Karlsson L, Warholic N, Kjems L, Horn P. Validation of the PRUCISION instruments in pediatric patients with progressive familial intrahepatic cholestasis. Adv Ther. 2022;39:5105\u201325. https:\/\/doi.org\/10.1007\/S12325-022-02262-7.","journal-title":"Adv Ther"},{"key":"3599_CR11","doi-asserted-by":"publisher","DOI":"10.15252\/EMMM.202114563","author":"Q Pan","year":"2021","unstructured":"Pan Q, Luo G, Qu J, Chen S, Zhang X, Zhao N, Ding J, Yang H, Li M, Li L, et al. A homozygous R148W mutation in semaphorin 7A causes progressive familial intrahepatic cholestasis. EMBO Mol Med. 2021. https:\/\/doi.org\/10.15252\/EMMM.202114563.","journal-title":"EMBO Mol Med"},{"key":"3599_CR12","unstructured":"Home \u2013 OMIM. https:\/\/www.omim.org\/. Accessed 26 Apr 2023."},{"key":"3599_CR13","doi-asserted-by":"publisher","DOI":"10.2147\/HMER.S137209","author":"M Gunaydin","year":"2018","unstructured":"Gunaydin M, Tugce A, Cil B. Progressive familial intrahepatic cholestasis: diagnosis, management, and treatment. Hepat Med. 2018. https:\/\/doi.org\/10.2147\/HMER.S137209.","journal-title":"Hepat Med"},{"key":"3599_CR14","unstructured":"Fiche Info - ACIDE URSODESOXYCHOLIQUE BIOGARAN 250 Mg, Comprim\u00e9 Pellicul\u00e9 - Base de Donn\u00e9es Publique Des M\u00e9dicaments. https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=60970141. Accessed 10 Aug 2023."},{"key":"3599_CR15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/J.JHEP.2020.02.007","volume":"73","author":"DBE van Wessel","year":"2020","unstructured":"van Wessel DBE, Thompson RJ, Gonzales E, Jankowska I, Sokal E, Grammatikopoulos T, Kadaristiana A, Jacquemin E, Spraul A, Lipi\u0144ski P, et al. Genotype correlates with the natural history of severe bile salt export pump deficiency. J Hepatol. 2020;73:84\u201393. https:\/\/doi.org\/10.1016\/J.JHEP.2020.02.007.","journal-title":"J Hepatol"},{"key":"3599_CR16","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/S2468-1253(22)00093-0","volume":"7","author":"RJ Thompson","year":"2022","unstructured":"Thompson RJ, Arnell H, Artan R, Baumann U, Calvo PL, Czubkowski P, Dalgic B, D\u2019Antiga L, Durmaz \u00d6, Fischler B, et al. Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2022;7:830\u201342. https:\/\/doi.org\/10.1016\/S2468-1253(22)00093-0.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3599_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/J.JHEPR.2022.100590","author":"M Biyoukar","year":"2022","unstructured":"Biyoukar M, Corpechot C, El Mouhadi S, Chambenois E, Vanderbecq Q, Barbu V, Dong C, Lemoinne S, Tordjman M, Jomaah R, et al. A BCB4 variant is associated with hepatobiliary MR abnormalities in people with low-phospholipid-associated cholelithiasis syndrome. JHEP Rep. 2022. https:\/\/doi.org\/10.1016\/J.JHEPR.2022.100590.","journal-title":"JHEP Rep"},{"key":"3599_CR18","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S1089-3261(03)00133-8","volume":"8","author":"VA Luketic","year":"2004","unstructured":"Luketic VA, Shiffman ML. Benign recurrent intrahepatic cholestasis. Clin Liver Dis. 2004;8:133\u201349. https:\/\/doi.org\/10.1016\/S1089-3261(03)00133-8.","journal-title":"Clin Liver Dis"},{"key":"3599_CR19","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1111\/APT.16118","volume":"52","author":"JS Nayagam","year":"2020","unstructured":"Nayagam JS, Williamson C, Joshi D, Thompson RJ. Review article: liver disease in adults with variants in the cholestasis-related genes ABCB11, ABCB4 and ATP8B1. Aliment Pharmacol Ther. 2020;52:1628\u201339. https:\/\/doi.org\/10.1111\/APT.16118.","journal-title":"Aliment Pharmacol Ther"},{"key":"3599_CR20","doi-asserted-by":"publisher","unstructured":"Vitale G, Mattiaccio A, Conti A, Berardi S, Vero V, Turco L, Seri M, Morelli MC. Molecular and clinical links between drug-induced cholestasis and familial intrahepatic cholestasis. 2023. https:\/\/doi.org\/10.3390\/ijms24065823","DOI":"10.3390\/ijms24065823"},{"key":"3599_CR21","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/S00535-017-1423-1\/METRICS","volume":"53","author":"G Vitale","year":"2018","unstructured":"Vitale G, Gitto S, Raimondi F, Mattiaccio A, Mantovani V, Vukotic R, D\u2019Errico A, Seri M, Russell RB, Andreone P. Cryptogenic cholestasis in young and adults: ATP8B1, ABCB11, ABCB4, and TJP2 gene variants analysis by high-throughput sequencing. J Gastroenterol. 2018;53:945\u201358. https:\/\/doi.org\/10.1007\/S00535-017-1423-1\/METRICS.","journal-title":"J Gastroenterol"},{"key":"3599_CR22","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1002\/HEP4.2051","volume":"6","author":"JS Nayagam","year":"2022","unstructured":"Nayagam JS, Foskett P, Strautnieks S, Agarwal K, Miquel R, Joshi D, Thompson RJ. Clinical phenotype of adult-onset liver disease in patients with variants in ABCB4, ABCB11, and ATP8B1. Hepatol Commun. 2022;6:2654\u201364. https:\/\/doi.org\/10.1002\/HEP4.2051.","journal-title":"Hepatol Commun"},{"key":"3599_CR23","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/S0140-6736(18)31877-4","volume":"393","author":"C Ovadia","year":"2019","unstructured":"Ovadia C, Seed PT, Sklavounos A, Geenes V, Di Illio C, Chambers J, Kohari K, Bacq Y, Bozkurt N, Brun-Furrer R, et al. Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses. Lancet. 2019;393:899\u2013909. https:\/\/doi.org\/10.1016\/S0140-6736(18)31877-4.","journal-title":"Lancet"},{"key":"3599_CR24","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1186\/S13023-022-02565-6","volume":"17","author":"B Kruk","year":"2022","unstructured":"Kruk B, Milkiewicz M, Raszeja-Wyszomirska J, Milkiewicz P, Krawczyk M. A common variant in the hepatobiliary phospholipid transporter ABCB4 modulates liver injury in PBC but not in PSC: prospective analysis in 867 patients. Orphanet J Rare Dis. 2022;17:419. https:\/\/doi.org\/10.1186\/S13023-022-02565-6.","journal-title":"Orphanet J Rare Dis"},{"key":"3599_CR25","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1093\/CARCIN\/BGL249","volume":"28","author":"I Kim","year":"2007","unstructured":"Kim I, Morimura K, Shah Y, Yang Q, Ward JM, Gonzalez FJ. Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis. 2007;28:940\u20136. https:\/\/doi.org\/10.1093\/CARCIN\/BGL249.","journal-title":"Carcinogenesis"},{"key":"3599_CR26","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1001\/archpedi.1969.02100030114014","volume":"117","author":"RJ Clayton","year":"1969","unstructured":"Clayton RJ, Iber FL, Ruebner BH, Mckusick VA. Byler disease: fatal familial intrahepatic cholestasis in an amish kindred. Am J Dis Child. 1969;117:112\u201324. https:\/\/doi.org\/10.1001\/archpedi.1969.02100030114014.","journal-title":"Am J Dis Child"},{"key":"3599_CR27","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1093\/hmg\/4.6.1049","volume":"4","author":"VEH Carlton","year":"1995","unstructured":"Carlton VEH, Knisely AS, Freimer NB. Mapping of a locus for progressive familial intrahepatic cholestasis (byler disease) to 18q21-Q22, the benign recurrent intrahepatic cholestasis region. Hum Mol Genet. 1995;4:1049\u201353. https:\/\/doi.org\/10.1093\/hmg\/4.6.1049.","journal-title":"Hum Mol Genet"},{"key":"3599_CR28","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1053\/J.GASTRO.2004.04.065","volume":"127","author":"SWC Van Mil","year":"2004","unstructured":"Van Mil SWC, Van Der Woerd WL, Van Der Brugge G, Sturm E, Jansen PLM, Bull LN, Van Den Berg IET, Berger R, Houwen RHJ, Klomp LWJ. Benign recurrent intrahepatic cholestasis type 2 is caused by mutations in ABCB11. Gastroenterology. 2004;127:379\u201384. https:\/\/doi.org\/10.1053\/J.GASTRO.2004.04.065.","journal-title":"Gastroenterology"},{"key":"3599_CR29","first-page":"282","volume":"95","author":"J Marleen","year":"1998","unstructured":"Marleen J, De Vree L, Jacquemin E, Cresteil D, Bosma PJ, Aten J, Deleuze J-F, Desrochers M, Burdelski M, Bernard O, et al. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Med Sci. 1998;95:282\u20137.","journal-title":"Med Sci"},{"key":"3599_CR30","doi-asserted-by":"publisher","first-page":"301","DOI":"10.2478\/JOMB-2014-0004","volume":"32","author":"M Gu\u017evi\u0107","year":"2013","unstructured":"Gu\u017evi\u0107 M. The history of DNA sequencing. J Med Biochem. 2013;32:301\u201312. https:\/\/doi.org\/10.2478\/JOMB-2014-0004.","journal-title":"J Med Biochem"},{"key":"3599_CR31","unstructured":"Challenges with Sanger Sequencing. https:\/\/www.news-medical.net\/life-sciences\/Challenges-with-Sanger-Sequencing.aspx. Accessed 1 Aug 2023."},{"key":"3599_CR32","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.jmoldx.2016.07.006","volume":"18","author":"W Mu","year":"2016","unstructured":"Mu W, Lu HM, Chen J, Li S, Elliott AM. Sanger confirmation is required to achieve optimal sensitivity and specificity in next-generation sequencing panel testing. J Mol Diagn. 2016;18:923\u201332. https:\/\/doi.org\/10.1016\/j.jmoldx.2016.07.006.","journal-title":"J Mol Diagn"},{"key":"3599_CR33","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.4254\/wjh.v13.i12.2024","volume":"13","author":"V Vinayagamoorthy","year":"2021","unstructured":"Vinayagamoorthy V, Srivastava A, Sarma M. Sen newer variants of progressive familial intrahepatic cholestasis. World J Hepatol. 2021;13:2024\u201338. https:\/\/doi.org\/10.4254\/wjh.v13.i12.2024.","journal-title":"World J Hepatol"},{"key":"3599_CR34","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/hep4.1320","volume":"3","author":"A \u00dcnl\u00fcsoy Aksu","year":"2019","unstructured":"\u00dcnl\u00fcsoy Aksu A, Das SK, Nelson-Williams C, Jain D, \u00d6zbay Ho\u015fnut F, Evirgen \u015eahin G, Lifton RP, Vilarinho S. Recessive mutations in KIF12 cause high gamma-glutamyltransferase cholestasis. Hepatol Commun. 2019;3:471\u20137. https:\/\/doi.org\/10.1002\/hep4.1320.","journal-title":"Hepatol Commun"},{"key":"3599_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/JCM10030481","volume":"10","author":"D Aldrian","year":"2021","unstructured":"Aldrian D, Vogel GF, Frey TK, Civan HA, Aksu A\u00dc, Avitzur Y, Ramos EB, \u00c7ak\u0131r M, Demir AM, Deppisch C, et al. Congenital diarrhea and cholestatic liver disease: phenotypic spectrum associated with MYO5B mutations. J Clin Med. 2021;10:1\u201315. https:\/\/doi.org\/10.3390\/JCM10030481.","journal-title":"J Clin Med"},{"key":"3599_CR36","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1002\/HUMU.23770","volume":"40","author":"YL Qiu","year":"2019","unstructured":"Qiu YL, Liu T, Abuduxikuer K, Hao CZ, Gong JY, Zhang MH, Li LT, Yan YY, Li JQ, Wang JS. Novel missense mutation in VPS33B is associated with isolated low gamma-glutamyltransferase cholestasis: attenuated, incomplete phenotype of arthrogryposis, renal dysfunction, and cholestasis syndrome. Hum Mutat. 2019;40:2247\u201357. https:\/\/doi.org\/10.1002\/HUMU.23770.","journal-title":"Hum Mutat"},{"key":"3599_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/J.GIM.2024.101231","author":"S Maddirevula","year":"2024","unstructured":"Maddirevula S, Shagrani M, Ji AR, Horne CR, Young SN, Mather LJ, Alqahtani M, McKerlie C, Wood G, Potter PK, et al. Large-scale genomic investigation of pediatric cholestasis reveals a novel hepatorenal ciliopathy caused by PSKH1 mutations. Genet Med. 2024. https:\/\/doi.org\/10.1016\/J.GIM.2024.101231.","journal-title":"Genet Med"},{"key":"3599_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/S12929-018-0475-8","author":"HL Chen","year":"2018","unstructured":"Chen HL, Wu SH, Hsu SH, Liou BY, Chen HL, Chang MH. Jaundice revisited: recent advances in the diagnosis and treatment of inherited cholestatic liver diseases. J Biomed Sci. 2018. https:\/\/doi.org\/10.1186\/S12929-018-0475-8.","journal-title":"J Biomed Sci"},{"key":"3599_CR39","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/J.JMOLDX.2021.07.028","volume":"23","author":"Y Yang","year":"2021","unstructured":"Yang Y, Zhang J, Li LT, Qiu YL, Gong JY, Zhang MH, Li CH, Wang JS. Whole-genome sequencing reveals large ATP8B1 deletion\/duplications as second mutations missed by exome-based sequencing. J Mol Diagn. 2021;23:1491\u20139. https:\/\/doi.org\/10.1016\/J.JMOLDX.2021.07.028.","journal-title":"J Mol Diagn"},{"key":"3599_CR40","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1136\/GUTJNL-2014-306896","volume":"64","author":"R Gordo-Gilart","year":"2015","unstructured":"Gordo-Gilart R, Andueza S, Hierro L, Mart\u00ednez-Fern\u00e1ndez P, D\u2019Agostino D, Jara P, Alvarez L. Functional analysis of ABCB4 mutations relates clinical outcomes of progressive familial intrahepatic cholestasis type 3 to the degree of MDR3 floppase activity. Gut. 2015;64:147\u201355. https:\/\/doi.org\/10.1136\/GUTJNL-2014-306896.","journal-title":"Gut"},{"key":"3599_CR41","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1093\/HMG\/DDH261","volume":"13","author":"L Alvarez","year":"2004","unstructured":"Alvarez L, Jara P, S\u00e1nchez-Sabat\u00e9 E, Hierro L, Larrauri J, D\u00edaz MC, Camarena C, De la Vega A, Frauca E, L\u00f3pez-Collazo E, et al. Reduced hepatic expression of farnesoid X receptor in hereditary cholestasis associated to mutation in ATP8B1. Hum Mol Genet. 2004;13:2451\u201360. https:\/\/doi.org\/10.1093\/HMG\/DDH261.","journal-title":"Hum Mol Genet"},{"key":"3599_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2023.1173542","author":"S Xie","year":"2023","unstructured":"Xie S, Wei S, Ma X, Wang R, He T, Zhang Z, Yang J, Wang J, Chang L, Jing M, et al. Genetic alterations and molecular mechanisms underlying hereditary intrahepatic cholestasis. Front Pharmacol. 2023. https:\/\/doi.org\/10.3389\/FPHAR.2023.1173542.","journal-title":"Front Pharmacol"},{"key":"3599_CR43","doi-asserted-by":"publisher","DOI":"10.1053\/J.GASTRO.2008.01.038","author":"SS Strautnieks","year":"2008","unstructured":"Strautnieks SS, Byrne JA, Pawlikowska L, Cebecauerov\u00e1 D, Rayner A, Dutton L, Meier Y, Antoniou A, Stieger B, Arnell H, et al. severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families. Gastroenterology. 2008. https:\/\/doi.org\/10.1053\/J.GASTRO.2008.01.038.","journal-title":"Gastroenterology"},{"key":"3599_CR44","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1038\/sj.ejhg.5201908","volume":"15","author":"D Degiorgio","year":"2007","unstructured":"Degiorgio D, Colombo C, Seia M, Porcaro L, Costantino L, Zazzeron L, Bordo D, Coviello DA. Molecular characterization and structural implications of 25 new ABCB4 mutations in progressive familial intrahepatic cholestasis type 3 (PFIC3). Eur J Hum Genet. 2007;15:1230\u20138. https:\/\/doi.org\/10.1038\/sj.ejhg.5201908.","journal-title":"Eur J Hum Genet"},{"key":"3599_CR45","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/ng.2918","volume":"46","author":"M Sambrotta","year":"2014","unstructured":"Sambrotta M, Strautnieks S, Papouli E, Rushton P, Clark BE, Parry DA, Logan CV, Newbury LJ, Kamath BM, Ling S, et al. Mutations in TJP2 cause progressive cholestatic liver disease. Nat Genet. 2014;46:326\u20138. https:\/\/doi.org\/10.1038\/ng.2918.","journal-title":"Nat Genet"},{"key":"3599_CR46","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1002\/HEP.27872","volume":"62","author":"S Zhou","year":"2015","unstructured":"Zhou S, Hertel PM, Finegold MJ, Wang L, Kerkar N, Wang J, Wong LJC, Plon SE, Sambrotta M, Foskett P, et al. Hepatocellular carcinoma associated with tight-junction protein 2 deficiency. Hepatology. 2015;62:1914\u20136. https:\/\/doi.org\/10.1002\/HEP.27872.","journal-title":"Hepatology"},{"key":"3599_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/J.CLINRE.2023.102185","author":"A Di Giorgio","year":"2023","unstructured":"Di Giorgio A, Sciveres M, Fuoti M, Sonzogni A, Mandato C, D\u2019Antiga L. Treatment with an ileal bile acid transporter inhibitor in patients with TJP2 deficiency. Clin Res Hepatol Gastroenterol. 2023. https:\/\/doi.org\/10.1016\/J.CLINRE.2023.102185.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"3599_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10713","author":"N Gomez-Ospina","year":"2016","unstructured":"Gomez-Ospina N, Potter CJ, Xiao R, Manickam K, Kim MS, Kim KH, Shneider BL, Picarsic JL, Jacobson TA, Zhang J, et al. Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis. Nat Commun. 2016. https:\/\/doi.org\/10.1038\/ncomms10713.","journal-title":"Nat Commun"},{"key":"3599_CR49","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/S12519-011-0299-Z","volume":"8","author":"XQ Chen","year":"2012","unstructured":"Chen XQ, Wang LL, Shan QW, Tang Q, Deng YN, Lian SJ, Yun X. A novel heterozygous NR1H4 termination codon mutation in idiopathic infantile cholestasis. World J Pediatr. 2012;8:67\u201371. https:\/\/doi.org\/10.1007\/S12519-011-0299-Z.","journal-title":"World J Pediatr"},{"key":"3599_CR50","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1097\/MPG.0000000000002926","volume":"72","author":"LN Bull","year":"2021","unstructured":"Bull LN, Ellmers R, Foskett P, Strautnieks S, Sambrotta M, Czubkowski P, Jankowska I, Wagner B, Deheragoda M, Thompson RJ. Cholestasis due to USP53 deficiency. J Pediatr Gastroenterol Nutr. 2021;72:667\u201373. https:\/\/doi.org\/10.1097\/MPG.0000000000002926.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"3599_CR51","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1038\/s41436-018-0288-x","volume":"21","author":"S Maddirevula","year":"2019","unstructured":"Maddirevula S, Alhebbi H, Alqahtani A, Algoufi T, Alsaif HS, Ibrahim N, Abdulwahab F, Barr M, Alzaidan H, Almehaideb A, et al. Identification of novel loci for pediatric cholestatic liver disease defined by KIF12, PPM1F, USP53, LSR, and WDR83OS pathogenic variants. Genet Med. 2019;21:1164\u201372. https:\/\/doi.org\/10.1038\/s41436-018-0288-x.","journal-title":"Genet Med"},{"key":"3599_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/S13023-021-01775-8","author":"C Mandato","year":"2021","unstructured":"Mandato C, Siano MA, Nazzaro L, Gelzo M, Francalanci P, Rizzo F, D\u2019Agostino Y, Morleo M, Brillante S, Weisz A, et al. A ZFYVE19 gene mutation associated with neonatal cholestasis and cilia dysfunction: case report with a novel pathogenic variant. Orphanet J Rare Dis. 2021. https:\/\/doi.org\/10.1186\/S13023-021-01775-8.","journal-title":"Orphanet J Rare Dis"},{"key":"3599_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/FPED.2023.1061535\/FULL","author":"A Pepe","year":"2023","unstructured":"Pepe A, Colucci A, Carucci M, Nazzaro L, Bucci C, Ranucci G, Di Giorgio A, Vajro P, Mandato C. Case report: add-on treatment with odevixibat in a new subtype of progressive familial intrahepatic cholestasis broadens the therapeutic horizon of genetic cholestasis. Front Pediatr. 2023. https:\/\/doi.org\/10.3389\/FPED.2023.1061535\/FULL.","journal-title":"Front Pediatr"},{"key":"3599_CR54","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1097\/MPG.0000000000002740","volume":"71","author":"I Cockar","year":"2020","unstructured":"Cockar I, Foskett P, Strautnieks S, Clinch Y, Fustok J, Rahman O, Sutton H, Mtegha M, Fessatou S, Kontaki E, et al. Mutations in myosin 5B in children with early-onset cholestasis. J Pediatr Gastroenterol Nutr. 2020;71:184\u20138. https:\/\/doi.org\/10.1097\/MPG.0000000000002740.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"3599_CR55","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/LIV.15200","volume":"42","author":"ED Pfister","year":"2022","unstructured":"Pfister ED, Dr\u00f6ge C, Liebe R, Stalke A, Buhl N, Ballauff A, Cantz T, Bueltmann E, Stindt J, Luedde T, et al. Extrahepatic manifestations of progressive familial intrahepatic cholestasis syndromes: presentation of a case series and literature review. Liver Int. 2022;42:1084\u201396. https:\/\/doi.org\/10.1111\/LIV.15200.","journal-title":"Liver Int"},{"key":"3599_CR56","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/J.JHEP.2017.07.004","volume":"67","author":"C Dr\u00f6ge","year":"2017","unstructured":"Dr\u00f6ge C, Bonus M, Baumann U, Klindt C, Lainka E, Kathemann S, Brinkert F, Grabhorn E, Pfister ED, Wenning D, et al. Sequencing of FIC1, BSEP and MDR3 in a large cohort of patients with cholestasis revealed a high number of different genetic variants. J Hepatol. 2017;67:1253\u201364. https:\/\/doi.org\/10.1016\/J.JHEP.2017.07.004.","journal-title":"J Hepatol"},{"key":"3599_CR57","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/HEP.28779","volume":"65","author":"E Gonzales","year":"2017","unstructured":"Gonzales E, Taylor SA, Davit-Spraul A, Th\u00e9baut A, Thomassin N, Guettier C, Whitington PF, Jacquemin E. MYO5B mutations cause cholestasis with normal serum gamma-glutamyl transferase activity in children without microvillous inclusion disease. Hepatology. 2017;65:164\u201373. https:\/\/doi.org\/10.1002\/HEP.28779.","journal-title":"Hepatology"},{"key":"3599_CR58","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1002\/HEP.29020\/SUPPINFO","volume":"65","author":"YL Qiu","year":"2017","unstructured":"Qiu YL, Gong JY, Feng JY, Wang RX, Han J, Liu T, Lu Y, Li LT, Zhang MH, Sheps JA, et al. Defects in myosin VB are associated with a spectrum of previously undiagnosed low \u03b3-glutamyltransferase cholestasis. Hepatology. 2017;65:1655\u201369. https:\/\/doi.org\/10.1002\/HEP.29020\/SUPPINFO.","journal-title":"Hepatology"},{"key":"3599_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/J.JHEPR.2020.100201","author":"C Dong","year":"2020","unstructured":"Dong C, Condat B, Picon-Coste M, Chr\u00e9tien Y, Potier P, Noblinski B, Arriv\u00e9 L, Hauuy MP, Barbu V, Maftouh A, et al. Low-phospholipid-associated cholelithiasis syndrome: prevalence, clinical features, and comorbidities. JHEP Rep. 2020. https:\/\/doi.org\/10.1016\/J.JHEPR.2020.100201.","journal-title":"JHEP Rep"},{"key":"3599_CR60","doi-asserted-by":"publisher","first-page":"477","DOI":"10.51821\/84.3.013","volume":"84","author":"A Halawi","year":"2021","unstructured":"Halawi A, Ibrahim N, Bitar R. Triggers of benign recurrent intrahepatic cholestasis and its pathophysiology: a review of literature. Acta Gastroenterol Belg. 2021;84:477\u201386. https:\/\/doi.org\/10.51821\/84.3.013.","journal-title":"Acta Gastroenterol Belg"},{"key":"3599_CR61","doi-asserted-by":"publisher","first-page":"5979","DOI":"10.3390\/JCM12185979","volume":"12","author":"K Kato","year":"2023","unstructured":"Kato K, Umetsu S, Togawa T, Ito K, Kawabata T, Arinaga-Hino T, Tsumura N, Yasuda R, Mihara Y, Kusano H, et al. Clinicopathologic features, genetics, treatment, and long-term outcomes in japanese children and young adults with benign recurrent intrahepatic cholestasis: a multicenter study. J Clin Med. 2023;12:5979. https:\/\/doi.org\/10.3390\/JCM12185979.","journal-title":"J Clin Med"},{"key":"3599_CR62","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/J.JHEP.2010.01.034","volume":"53","author":"L Pawlikowska","year":"2010","unstructured":"Pawlikowska L, Strautnieks S, Jankowska I, Czubkowski P, Emerick K, Antoniou A, Wanty C, Fischler B, Jacquemin E, Wali S, et al. Differences in presentation and progression between severe FIC1 and BSEP deficiencies. J Hepatol. 2010;53:170\u20138. https:\/\/doi.org\/10.1016\/J.JHEP.2010.01.034.","journal-title":"J Hepatol"},{"key":"3599_CR63","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1055\/S-0030-1253223","volume":"30","author":"A Davit-Spraul","year":"2010","unstructured":"Davit-Spraul A, Gonzales E, Baussan C, Jacquemin E. The spectrum of liver diseases related to ABCB4 gene mutations: pathophysiology and clinical aspects. Semin Liver Dis. 2010;30:134\u201346. https:\/\/doi.org\/10.1055\/S-0030-1253223.","journal-title":"Semin Liver Dis"},{"key":"3599_CR64","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/HEP4.1088","volume":"1","author":"V Sundaram","year":"2017","unstructured":"Sundaram V, Bj\u00f6rnsson ES. Drug-induced cholestasis. Hepatol Commun. 2017;1:726\u201335. https:\/\/doi.org\/10.1002\/HEP4.1088.","journal-title":"Hepatol Commun"},{"key":"3599_CR65","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1002\/HEP.26424","volume":"58","author":"R Poupon","year":"2013","unstructured":"Poupon R, Rosmorduc O, Bo\u00eblle PY, Chr\u00e9tien Y, Corpechot C, Chazouill\u00e8res O, Housset C, Barbu V. Genotype-phenotype relationships in the low-phospholipid-associated cholelithiasis syndrome: a study of 156 consecutive patients. Hepatology. 2013;58:1105\u201310. https:\/\/doi.org\/10.1002\/HEP.26424.","journal-title":"Hepatology"},{"key":"3599_CR66","doi-asserted-by":"publisher","unstructured":"Kumari A, Kumar A, Kumar M, Swati S. Feto-maternal effects of adding rifampicin to ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. 2022. https:\/\/doi.org\/10.7759\/cureus.32509","DOI":"10.7759\/cureus.32509"},{"key":"3599_CR67","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S2468-1253(21)00074-1","volume":"6","author":"C Ovadia","year":"2021","unstructured":"Ovadia C, Sajous J, Seed PT, Patel K, Williamson NJ, Attilakos G, Azzaroli F, Bacq Y, Batsry L, Broom K, et al. Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis. Lancet Gastroenterol Hepatol. 2021;6:547\u201358. https:\/\/doi.org\/10.1016\/S2468-1253(21)00074-1.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3599_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/J.JHEP.2024.04.006","author":"HJ Verkade","year":"2024","unstructured":"Verkade HJ, Felzen A, Keitel V, Thompson R, Gonzales E, Strnad P, Kamath B, van Mil S. EASL clinical practice guidelines on genetic cholestatic liver diseases. J Hepatol. 2024. https:\/\/doi.org\/10.1016\/J.JHEP.2024.04.006.","journal-title":"J Hepatol"},{"key":"3599_CR69","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.aohep.2019.09.010","volume":"19","author":"E Sticova","year":"2020","unstructured":"Sticova E, Jirsa M. ABCB4 disease: many faces of one gene deficiency. Ann Hepatol. 2020;19:126\u201333. https:\/\/doi.org\/10.1016\/j.aohep.2019.09.010.","journal-title":"Ann Hepatol"},{"key":"3599_CR70","doi-asserted-by":"crossref","unstructured":"Knisely AS, Strautnieks SS, Meier Y, Stieger B, Byrne JA et al. Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency. Hepatology 2006.","DOI":"10.1002\/hep.21287"},{"key":"3599_CR71","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/NG.3247","volume":"47","author":"DF Gudbjartsson","year":"2015","unstructured":"Gudbjartsson DF, Helgason H, Gudjonsson SA, Zink F, Oddson A, Gylfason A, Besenbacher S, Magnusson G, Halldorsson BV, Hjartarson E, et al. Large-scale whole-genome sequencing of the icelandic population. Nat Genet. 2015;47:435\u201344. https:\/\/doi.org\/10.1038\/NG.3247.","journal-title":"Nat Genet"},{"key":"3599_CR72","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.dld.2021.09.011","volume":"54","author":"G Ranucci","year":"2022","unstructured":"Ranucci G, Della Corte C, Alberti D, Bondioni MP, Boroni G, Calvo PL, Cananzi M, Candusso M, Clemente MG, D\u2019Antiga L, et al. Diagnostic approach to neonatal and infantile cholestasis: a position paper by the SIGENP liver disease working group. Dig Liver Dis. 2022;54:40\u201353. https:\/\/doi.org\/10.1016\/j.dld.2021.09.011.","journal-title":"Dig Liver Dis"},{"key":"3599_CR73","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1002\/jgc4.1207","volume":"29","author":"L Jamal","year":"2020","unstructured":"Jamal L, Schupmann W, Berkman BE. An ethical framework for genetic counseling in the genomic era HHS public access. J Genet Couns. 2020;29:718\u201327. https:\/\/doi.org\/10.1002\/jgc4.1207.","journal-title":"J Genet Couns"},{"key":"3599_CR74","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jhep.2023.11.028","volume":"80","author":"JS Nayagam","year":"2024","unstructured":"Nayagam JS, Miquel R, Thompson RJ, Joshi D. Genetic cholestasis in children and adults. J Hepatol. 2024;80:670\u20132. https:\/\/doi.org\/10.1016\/j.jhep.2023.11.028.","journal-title":"J Hepatol"},{"key":"3599_CR75","doi-asserted-by":"publisher","first-page":"13376","DOI":"10.3390\/IJMS232113376","volume":"23","author":"K Zdanowicz","year":"2022","unstructured":"Zdanowicz K, Daniluk J, Lebensztejn DM, Daniluk U. The etiology of cholelithiasis in children and adolescents\u2014a literature review. Int J Mol Sci. 2022;23:13376. https:\/\/doi.org\/10.3390\/IJMS232113376.","journal-title":"Int J Mol Sci"},{"key":"3599_CR76","doi-asserted-by":"publisher","first-page":"649","DOI":"10.3760\/CMA.J.CN112140-20240319-00190","volume":"62","author":"X Ye","year":"2024","unstructured":"Ye X, Yu F, Zhou J, Zhao C, Wu J. Clinical phenotype and genotype analysis of progressive familial intrahepatic cholestasis type 3 caused by novel ABCB4 gene mutation. Zhonghua Er Ke Za Zhi. 2024;62:649\u201354. https:\/\/doi.org\/10.3760\/CMA.J.CN112140-20240319-00190.","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"3599_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/J.EBIOM.2023.104747","author":"M Zheng","year":"2023","unstructured":"Zheng M, Hakim A, Konkwo C, Deaton AM, Ward LD, Silveira MG, Assis DN, Liapakis AM, Jaffe A, Jiang ZG, et al. Advancing diagnosis and management of liver disease in adults through exome sequencing. EBioMedicine. 2023. https:\/\/doi.org\/10.1016\/J.EBIOM.2023.104747.","journal-title":"EBioMedicine"},{"key":"3599_CR78","doi-asserted-by":"publisher","DOI":"10.3390\/MOLECULES27227830","author":"Y Shansky","year":"2022","unstructured":"Shansky Y, Bespyatykh J. Bile acids: physiological activity and perspectives of using in clinical and laboratory diagnostics. Molecules. 2022. https:\/\/doi.org\/10.3390\/MOLECULES27227830.","journal-title":"Molecules"},{"key":"3599_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/S41598-023-39977-8","author":"F Chen","year":"2023","unstructured":"Chen F, Yao Y, Li Z, Deng L, He R. Assessment of compensated advanced chronic liver disease based on serum bile acids in chronic hepatitis B patients. Sci Rep. 2023. https:\/\/doi.org\/10.1038\/S41598-023-39977-8.","journal-title":"Sci Rep"},{"key":"3599_CR80","doi-asserted-by":"publisher","first-page":"e211","DOI":"10.1016\/j.jhep.2023.05.049","volume":"79","author":"JS Nayagam","year":"2023","unstructured":"Nayagam JS, Masson S, Ferguson JW, Griffiths W, Joshi D. Where does genetic testing fit in the diagnostic pathway of patients with cryptogenic cirrhosis? J Hepatol. 2023;79:e211\u20133. https:\/\/doi.org\/10.1016\/j.jhep.2023.05.049.","journal-title":"J Hepatol"},{"key":"3599_CR81","doi-asserted-by":"publisher","first-page":"104747","DOI":"10.1016\/J.EBIOM.2023.104747","volume":"95","author":"M Zheng","year":"2023","unstructured":"Zheng M, Hakim A, Konkwo C, Deaton AM, Ward LD, Silveira MG, Assis DN, Liapakis AM, Jaffe A, Jiang ZG, et al. Advancing diagnosis and management of liver disease in adults through exome sequencing. EBioMedicine. 2023;95:104747. https:\/\/doi.org\/10.1016\/J.EBIOM.2023.104747.","journal-title":"EBioMedicine"},{"key":"3599_CR82","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1016\/J.BBADIS.2017.07.029","volume":"1864","author":"MC Reichert","year":"2018","unstructured":"Reichert MC, Hall RA, Krawczyk M, Lammert F. Genetic determinants of cholangiopathies: molecular and systems genetics. Biochim Biophys Acta (BBA) Mol Basis Dis. 2018;1864:1484\u201390. https:\/\/doi.org\/10.1016\/J.BBADIS.2017.07.029.","journal-title":"Biochim Biophys Acta (BBA) Mol Basis Dis"},{"key":"3599_CR83","unstructured":"ClinVar. https:\/\/www.ncbi.nlm.nih.gov\/clinvar\/. Accessed 4 Aug 2023."},{"key":"3599_CR84","unstructured":"ATP8B1[Gene] - ClinVar \u2013 NCBI. https:\/\/www.ncbi.nlm.nih.gov\/clinvar\/?term=ATP8B1%5Bgene%5D. Accessed 7 Jun 2023."},{"key":"3599_CR85","doi-asserted-by":"publisher","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the american college of medical genetics and genomics and the association for molecular pathology. 2015. https:\/\/doi.org\/10.1038\/gim.2015.30","DOI":"10.1038\/gim.2015.30"},{"key":"3599_CR86","unstructured":"GnomAD. https:\/\/gnomad.broadinstitute.org\/. Accessed 4 Aug 2023."},{"key":"3599_CR87","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1186\/S13023-022-02529-W","volume":"17","author":"N Denton","year":"2022","unstructured":"Denton N, Mulberg AE, Molloy M, Charleston S, Fajgenbaum DC, Marsh ED, Howard P. Sharing is caring: a call for a new era of rare disease research and development. Orphanet J Rare Dis. 2022;17:389. https:\/\/doi.org\/10.1186\/S13023-022-02529-W.","journal-title":"Orphanet J Rare Dis"},{"key":"3599_CR88","doi-asserted-by":"publisher","first-page":"100949","DOI":"10.1016\/j.jhepr.2023.100949","volume":"6","author":"P McKiernan","year":"2024","unstructured":"McKiernan P, Bernabeu JQ, Girard M, Indolfi G, Lurz E, Trivedi P. Opinion paper on the diagnosis and treatment of progressive familial intrahepatic cholestasis. JHEP Rep. 2024;6:100949. https:\/\/doi.org\/10.1016\/j.jhepr.2023.100949.","journal-title":"JHEP Rep"},{"key":"3599_CR89","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1002\/HEP4.1149","volume":"2","author":"SB Schatz","year":"2018","unstructured":"Schatz SB, J\u00fcngst C, Keitel-Anselmo V, Kubitz R, Becker C, Gerner P, Pfister ED, Goldschmidt I, Junge N, Wenning D, et al. Phenotypic spectrum and diagnostic pitfalls of ABCB4 deficiency depending on age of onset. Hepatol Commun. 2018;2:504\u201314. https:\/\/doi.org\/10.1002\/HEP4.1149.","journal-title":"Hepatol Commun"},{"key":"3599_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/DIAGNOSTICS12051169","author":"M Almes","year":"2022","unstructured":"Almes M, Spraul A, Ruiz M, Girard M, Roquelaure B, Laborde N, Gottrand F, Turquet A, Lamireau T, Dabadie A, et al. Targeted-capture next-generation sequencing in diagnosis approach of pediatric cholestasis. Diagnostics. 2022. https:\/\/doi.org\/10.3390\/DIAGNOSTICS12051169.","journal-title":"Diagnostics"},{"key":"3599_CR91","doi-asserted-by":"publisher","first-page":"100844","DOI":"10.1016\/j.jhepr.2023.100844","volume":"5","author":"E Gonzales","year":"2023","unstructured":"Gonzales E, Gardin A, Almes M, Darmellah-Remil A, Seguin H, Mussini C, Franchi-Abella S, Duch\u00e9 M, Ackermann O, Th\u00e9baut A, et al. Outcomes of 38 patients with PFIC3: impact of genotype and of response to ursodeoxycholic acid therapy. JHEP Rep. 2023;5:100844. https:\/\/doi.org\/10.1016\/j.jhepr.2023.100844.","journal-title":"JHEP Rep"},{"key":"3599_CR92","doi-asserted-by":"publisher","first-page":"e301","DOI":"10.1097\/PG9.0000000000000301","volume":"4","author":"R Ganschow","year":"2023","unstructured":"Ganschow R, Maucksch C. Odevixibat treatment of alagille syndrome: a case report. JPGN Rep. 2023;4:e301. https:\/\/doi.org\/10.1097\/PG9.0000000000000301.","journal-title":"JPGN Rep"},{"key":"3599_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/J.JHEPR.2023.100978","author":"T Herta","year":"2024","unstructured":"Herta T, Dr\u00f6ge C, Herber A, Keitel V, Berg T. Odevixibat treatment in an adult patient with advanced icteric progressive cholestatic liver disease. JHEP Rep. 2024. https:\/\/doi.org\/10.1016\/J.JHEPR.2023.100978.","journal-title":"JHEP Rep"},{"key":"3599_CR94","unstructured":"Trivedi P et al. Adult Patients with Genetic Disorders of Cholestasis Treated with Odevixibat. In: Poster presented at the annual meeting of the European association for the study of the live (EASL): the international liver congress; June 21\u201324, 2023 Vienna; 2023."},{"key":"3599_CR95","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/JCA.21573","volume":"33","author":"R Chkheidze","year":"2018","unstructured":"Chkheidze R, Joseph R, Burner J, Matevosyan K. Plasma exchange for the management of refractory pruritus of cholestasis: a report of three cases and review of literature. J Clin Apher. 2018;33:412\u20138. https:\/\/doi.org\/10.1002\/JCA.21573.","journal-title":"J Clin Apher"},{"key":"3599_CR96","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/JCA.21654","volume":"33","author":"C Ovadia","year":"2018","unstructured":"Ovadia C, L\u00f6vgren-Sandblom A, Edwards LA, Langedijk J, Geenes V, Chambers J, Cheng F, Clarke L, Begum S, Noori M, et al. Therapeutic plasma exchange as a novel treatment for severe intrahepatic cholestasis of pregnancy: case series and mechanism of action. J Clin Apher. 2018;33:638\u201344. https:\/\/doi.org\/10.1002\/JCA.21654.","journal-title":"J Clin Apher"},{"key":"3599_CR97","doi-asserted-by":"publisher","first-page":"644","DOI":"10.12659\/AOT.899462","volume":"21","author":"J Rajchert","year":"2016","unstructured":"Rajchert J, Rosa M, Paw\u0142owska J, Parczewski M, Wawrzynowicz-Syczewska M. Follow-up of pediatric liver transplant patients after reaching adulthood. Ann Transplant. 2016;21:644\u20138. https:\/\/doi.org\/10.12659\/AOT.899462.","journal-title":"Ann Transplant"},{"key":"3599_CR98","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10061238","author":"J Mart\u00ednez-Garc\u00eda","year":"2022","unstructured":"Mart\u00ednez-Garc\u00eda J, Molina A, Gonz\u00e1lez-Aseguinolaza G, Weber ND, Smerdou C. Gene therapy for acquired and genetic cholestasis. Biomedicines. 2022. https:\/\/doi.org\/10.3390\/biomedicines10061238.","journal-title":"Biomedicines"},{"key":"3599_CR99","unstructured":"Analysis of metabolic profiles of bile acids in urine using a lipophilic anion exchanger and computerized gas-liquid chromatorgaphy-mass spectrometry. https:\/\/pubmed.ncbi.nlm.nih.gov\/864325\/. Accessed 21 Jun 2023."},{"key":"3599_CR100","unstructured":"Sulfated and nonsulfated bile acids in urine, serum, and bile of patients with hepatobiliary diseases. https:\/\/pubmed.ncbi.nlm.nih.gov\/1112456\/. Accessed 21 Jun 2023."},{"key":"3599_CR101","unstructured":"Urinary bile acids in population screening for inapparent liver disease. https:\/\/pubmed.ncbi.nlm.nih.gov\/9840133\/. Accessed 21 Jun 2023."},{"key":"3599_CR102","unstructured":"Study Record | Beta ClinicalTrials.Gov. https:\/\/clinicaltrials.gov\/study\/NCT01200082?tab=history. Accessed 21 June 2023."},{"key":"3599_CR103","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1111\/liv.14553","volume":"40","author":"BM Kamath","year":"2020","unstructured":"Kamath BM, Stein P, Houwen RHJ, Verkade HJ. Potential of ileal bile acid transporter inhibition as a therapeutic target in alagille syndrome and progressive familial intrahepatic cholestasis. Liver Int. 2020;40:1812\u201322. https:\/\/doi.org\/10.1111\/liv.14553.","journal-title":"Liver Int"},{"key":"3599_CR104","unstructured":"Progressive Familial Intrahepatic Cholestasis (PFIC) \u2013 Baby Detect. https:\/\/babydetect.com\/en\/progressive-familial-intrahepatic-cholestasis-pfic-atp8b1-abcb11-abcb4-tjp2-nr1h4-and-myo5b-genes\/. Accessed 21 Jun 2023."},{"key":"3599_CR105","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01884-4","author":"T Jones-Hughes","year":"2021","unstructured":"Jones-Hughes T, Campbell J, Crathorne L. Epidemiology and burden of progressive familial intrahepatic cholestasis: a systematic review. Orphanet J Rare Dis. 2021. https:\/\/doi.org\/10.1186\/s13023-021-01884-4.","journal-title":"Orphanet J Rare Dis"},{"key":"3599_CR106","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0009-8981(01)00716-1","volume":"315","author":"A Clague","year":"2002","unstructured":"Clague A, Thomas A. neonatal biochemical screening for disease. Clin Chim Acta. 2002;315:99\u2013110. https:\/\/doi.org\/10.1016\/S0009-8981(01)00716-1.","journal-title":"Clin Chim Acta"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03599-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03599-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03599-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:56:55Z","timestamp":1740131815000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03599-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":106,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3599"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03599-2","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]},"assertion":[{"value":"16 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"80"}}